| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Zevra Therapeutics Inc. | ACER-001 | Maple Syrup Urine Disease (MSUD) | Phase 2a | Trial Planned | Oral | Genetic Disorder |
| Zevra Therapeutics Inc. | Osanetant (ACER-801) | induced Vasomotor Symptoms (iVMS) associated with menopause | Phase 2a | Clinical Pause | Oral | Women's Health |
| Zevra Therapeutics Inc. | ACER-001 | Maple Syrup Urine Disease (MSUD) | Phase 2a | Trial Planned | Oral | Genetic Disorder |
| Zevra Therapeutics Inc. | Osanetant (ACER-801) | induced Vasomotor Symptoms (iVMS) associated with menopause | Phase 2a | Clinical Pause | Oral | Women's Health |
| Zura Bio Limited | Torudokimab (ZB-880) | Asthma | Phase 2/3 | Ongoing | Intravenous | Respiratory |
| Zura Bio Limited | Tibulizumab (LY3090106) | Primary Sjogren's Syndrome | Phase 2/3 | Withdrawn | Intravenous | Immunology |
| Zura Bio Limited | Tibulizumab (ZB-106) - (TibuSURE) | Systemic Sclerosis | Phase 2 | Enrollment Initiation | Intravenous | Immunology |
| Zura Bio Limited | Tibulizumab (ZB-106) - (TibuSHIELD) | Hidradenitis Suppurativa | Phase 2 | Enrollment Initiation | Intravenous | Immunology: Anti-TNF |